This study evaluates multimodal [18F]DCFPyL positron emission tomography (PET)/magnetic resonance imaging (MRI) for solid tumor characterization and disease staging. This study may help doctors develop advanced imaging methods to more accurately characterize prostate cancer and other solid tumor aggressiveness.
Additional locations may be listed on ClinicalTrials.gov for NCT04687969.
Locations matching your search criteria
United States
Massachusetts
Boston
Massachusetts General Hospital Cancer CenterStatus: Active
Contact: Ciprian Catana
Phone: 617-643-4885
PRIMARY OBJECTIVE:
I. Develop and evaluate machine learning approaches (radiomics and deep learning) for predicting primary prostate cancer tumor aggressiveness from fluorine F 18 DCFPyL ([18F]DCFPYL) PET/MRI data.
SECONDARY OBJECTIVE:
I. Evaluate the utility of [18F]DCFPyl PET/MRI in the characterization of other solid tumors (hepatocellular carcinoma, glioma, clear cell renal carcinoma).
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT A: Patients receive [18F]DCFPyL intravenously (IV) and undergo PET/MRI scan. Patients may receive additional [18F]DCFPyL IV and undergo a second PET/MRI scan.
COHORT B: Patients receive [18F]DCFPyL IV and undergo PET/MRI scan up to 3 times.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationDana-Farber Harvard Cancer Center
Principal InvestigatorCiprian Catana